LYCOS RETRIEVER 
Genetics: Viral Genetics
built 608 days ago
The Advanced Concentration in Genetics is one of six graduate programs leadingto the Ph.D. degree under the auspices of the Interdisciplinary Program in Biomedical Sciences at the University of Florida College of Medicine. Faculty from the Departments of Biochemistry and Molecular Biology, Molecular Genetics and Microbiology, Medicine, Neuroscience, Pathology, Immunology & Laboratory Medicine, Pediatrics, and others join forces to offer students broad opportunities for graduate training in genetics. Graduates of the program are prepared to conduct research and assume supervisory and teaching responsibilities in all facets of modern molecular genetics, including human genetics, mammalian genetics, lower eukaryotic genetics, bacterial genetics, viral genetics, and immunogenetics.
Source:
Targeted Genetics has an established, state-of-the-art cGMP (current good manufacturing practice) manufacturing facility. Targeted Genetics' proprietary manufacturing process for its adeno-associated virus (AAV)-based products utilizes equipment and processes common to the biopharmaceutical industry. These processes are broadly applicable to the production of other viral vectors, such as adenovectors, as well as several other types of biologics. Targeted Genetics is continuing to explore several ways to utilize its manufacturing capacity to secure additional revenue.
Source:
Targeted Genetics is putting the bull's-eye on disease. The firm is developing gene therapy products to treat acquired and inherited diseases. Gene therapy involves the insertion of genes into cells to produce proteins necessary in addressing certain disease conditions. The firm concentrates its efforts on adeno-associated viral (AAV) vectors, which deliver genetic material to cells, for treating various diseases and conditions. Its lead AAV candidates, which are in clinical trials, target HIV/AIDS and rheumatoid arthritis. Its pipeline ... includes possible therapies for congestive heart failure and Huntington's disease.
Source:
Viral Genetics, Inc. is a biotechnology company that discovers and develops immune-based therapies for HIV and AIDS using its thymus nuclear protein compound. This compound may have other potential applications for other infectious, autoimmune, and immunological deficiency diseases that the company intends to study in the future. Viral Genetics believes that VGV-1 represents a significant and unique approach to treating HIV due to the apparently novel mechanism, low toxicity profile, simple dosing regimen, and short-course of treatment. Online at www.viralgenetics.com
Source:
/PRNewswire-FirstCall/ -- Viral Genetics, Inc. (VRAL - news) will present at the NYSSA 10th Annual Biotech and Specialty Pharmaceutical Conference on December 12, 2006 at 2:20PM. The conference is taking place at the NYSSA offices in midtown New York.
Source:
SALT LAKE CITY, Sept. 20 /PRNewswire/ -- Myriad Genetics, Inc. (Nasdaq: MYGN), today reported pre-clinical data on its lead Anti-HIV compound, MPI-49839. The drug addresses a novel mechanism in the viral-host interaction and holds the potential for an entirely new class of AIDS therapeutics.
Source:
MORE ABOUT
Viral Genetics